文献速递腹部MR

门静脉高压对钆塞酸增强肝脏磁共振的影响:诊断与预后意义

Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.
PubMed 文献 · Invest Radiol · 2017-01-01

回顾性研究178例慢性肝病患者,分析钆塞酸增强MRI延迟期表现与肝静脉压力梯度(HVPG)的关系。门静脉高信号征(PVHS)与重度门脉高压独立相关(OR 3.33),且较低相对肝脏强化(RLE)和PVHS与较低3年无移植生存率相关。

要点

  • 钆塞酸增强MRI延迟期出现门静脉高信号征(PVHS)提示重度门脉高压可能。
  • PVHS与重度门脉高压独立相关(OR 3.33),独立于脾大、侧支循环和腹水。
  • 较低RLE和PVHS与较低3年无移植生存率相关。

核心结论

  • 钆塞酸增强MRI上门静脉高信号征是重度门脉高压的独立指标,可能有助于更准确诊断;该征象和肝对比剂摄取降低也可能提供预后信息。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,纳入178例慢性肝病患者(142例男性,中位年龄59.4岁),于2008年1月至2015年4月间接受MRI和肝静脉压力梯度(HVPG)测量;MRI评估门脉高压既定特征和20分钟延迟T1加权钆塞酸增强MRI特征(相对肝脏强化RLE、胆道对比剂排泄、门静脉高信号或等信号即PVHS);统计方法包括线性回归、逻辑回归和生存分析。

关键影像表现/征象

  • 延迟20分钟T1加权钆塞酸增强MRI上门静脉高信号征(PVHS)定义为门静脉高信号或等信号。
  • 延迟期胆道对比剂排泄可见于33例患者。
  • 门脉高压既定影像特征包括脾脏和门静脉直径、门体侧支循环(81例)和腹水(88例)。

诊断标准与关键数值

  • 临床显著门脉高压定义为HVPG≥10 mm Hg(109例),重度门脉高压定义为HVPG≥12 mm Hg(99例)。
  • 单变量分析中,临床显著门脉高压和重度门脉高压均与延迟胆道对比剂排泄(33例)和PVHS(74例)相关(所有P<0.01)。
  • 多变量分析显示PVHS与重度门脉高压显著相关(OR 3.33,P=0.008),独立于脾脏大小(OR 1.26,P=0.002)、门体侧支循环(81例,OR 5.46,P=0.0001)和腹水(88例,OR 3.24,P=0.006)。
  • 较低RLE和PVHS与较低3年无移植生存率相关(风险比分别为0.98和3.99,所有P=0.002),独立于Child-Pugh和终末期肝病模型评分。
  • HVPG与RLE呈负相关(r=0.18,P<0.0001)。

临床应用与阅片要点

  • 在阅片时,可关注钆塞酸增强MRI延迟20分钟T1加权图像上门静脉高信号征(PVHS),该征象与重度门脉高压独立相关。
  • 延迟期胆道对比剂排泄和PVHS在临床显著门脉高压和重度门脉高压患者中更常见(所有P<0.01)。
  • 较低RLE和PVHS可能提供预后信息,与较低3年无移植生存率相关(风险比分别为0.98和3.99,所有P=0.002)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of this study was to investigate the impact of portal hypertension (PH) on gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) and assess diagnostic and prognostic implications in comparison to established imaging features of PH.

MATERIALS AND METHODS: Institutional review board-approved retrospective study of 178 patients (142 men; median age, 59.4 years) with chronic liver disease undergoing MRI and hepatic venous pressure gradient (HVPG) measurement between January 2008 and April 2015. Magnetic resonance imaging was assessed for established features of PH (splenic and portal vein diameters, portosystemic collaterals, ascites) and for features on 20 minutes delayed T1-weighted gadoxetic acid-enhanced MRI, that is, relative liver enhancement (RLE), biliary contrast excretion, or portal vein hyperintensity or isointensity (ie, portal vein hyperintensity sign, PVHS). Statistics encompassed linear regression, logistic regression, and survival analysis.

RESULTS: There was an inverse correlation between HVPG and RLE (r = 0.18, P < 0.0001). On univariate analysis, clinically significant PH (ie, HVPG ≥ 10 mm Hg, n = 109) and severe PH (ie, HVPG ≥ 12 mm Hg, n = 99) were associated with delayed biliary contrast excretion (n = 33) and the PVHS (n = 74) (P < 0.01 for all). Multivariate analysis demonstrated significant associations between the PVHS and severe PH (odds ratio [OR], 3.33; P = 0.008), independently of spleen size (OR, 1.26; P = 0.002), portosystemic collaterals (n = 81; OR, 5.46; P = 0.0001), and ascites (n = 88; OR, 3.24; P = 0.006). Lower RLE and the PVHS were associated with lower 3-year, transplantation-free survival (hazards ratios, 0.98 and 3.99, respectively, P = 0.002 for all), independently of the Child-Pugh and Model for End-Stage Liver Disease scores.

CONCLUSIONS: The presence of the PVHS on gadoxetic acid-enhanced MRI is an independent indicator of severe PH and may enable more accurate diagnosis. This feature and decreased hepatic contrast uptake may also comprise prognostic information.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Asenbaum U, Ba-Ssalamah A, Mandorfer M, et al. Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. Invest Radiol. 2017. PMID: 28622247. doi:10.1097/RLI.0000000000000366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。